Across TCGA pan-cancer cohorts, B3GLCT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated B3GLCT data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher B3GLCT mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated B3GLCT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

UCEC, COAD, and CCRCC are the cancer types where B3GLCT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	0.386	1.000	.002	32	view →
COAD	DFS	Median	III,IV	0.822	1.000	.021	24	view →
CCRCC	DFS	Tertile	II,III,IV	0.889	0.460	<.001	13	view →
HNSC	OS	Median	III,IV	1.000	0.484	.038	5	view →
LUAD	DFS	Tertile	II,III,IV	0.861	0.270	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: B3GLCT tumor-vs-normal RNA expression · all B3GLCT data types